drugset

drugset / Trial / NCT05747326

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

NCT05747326 ↗

Phase 2 Unknown 30 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

NaSingle-groupOpen-labelTreatment

Summary

This study was a prospective, single-arm, open-label phase II clinical trial conducted at National cancer center in China.

Timeline

Start: 2022-01-01
Primary completion: 2023-06-01
Completion: 2023-06

Publications

Chai Y, Liu J, Jiang M, He M, Wang Z, Ma F, Wang J, Yuan P, Luo Y, Xu B, Li Q. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer. Thorac Cancer. 2023 Aug;14(23):2259-2268. doi: 10.1111/1759-7714.15011. Epub 2023 Jul 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	500 mg	Oral
Subject	Vinorelbine	Small molecule	40 mg	Oral

Indications